
Calogero Camma'

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6809204/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serial combination of nonâ€invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <scp>NAFLD</scp> . Alimentary Pharmacology and Therapeutics, 2017, 46, 617-627.	1.9	134
2	ls early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with directâ€acting antivirals? A prospective multicentre study. Alimentary Pharmacology and Therapeutics, 2017, 46, 688-695.	1.9	124
3	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2012, 56, 850-860.	3.6	97
4	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1046-1054.	3.6	89
5	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2014, 59, 1692-1705.	3.6	75
6	A metaâ€analysis of single <scp>HCV</scp> â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp> â€related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	1.9	70
7	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut, 2022, 71, 593-604.	6.1	62
8	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An ageâ€dependent risk profiling study. Liver International, 2017, 37, 1389-1396.	1.9	44
9	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. Digestive and Liver Disease, 2015, 47, 324-330.	0.4	43
10	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. Journal of Hepatology, 2013, 59, 658-666.	1.8	41
11	Usefulness of the index of <scp>NASH</scp> – <scp>ION</scp> for the diagnosis of steatohepatitis in patients with nonâ€alcoholic fatty liver: An external validation study. Liver International, 2018, 38, 715-723.	1.9	22
12	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. Liver International, 2018, 38, 2108-2116.	1.9	20
13	Liverâ€related and extrahepatic events in patients with nonâ€alcoholic fatty liver disease: a retrospective competing risks analysis. Alimentary Pharmacology and Therapeutics, 2022, 55, 604-615.	1.9	18
14	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 936-942.	0.4	17
15	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. Liver International, 2021, 41, 1105-1116.	1.9	10
16	<i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	1.9	6
17	Longâ€ŧerm evolution of Llâ€RADS observations in HCVâ€related cirrhosis treated with directâ€acting antivirals. Liver International, 2021, 41, 2179-2188.	1.9	3
18	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International. O	0.2	3

#	Article	IF	CITATIONS
19	Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation – authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 35, 862-863.	1.9	1